Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-Center, Randomized Phase III Study of Neoadjuvant Anti-PD-1 Immunotherapy Plus TP Chemotherapy Versus TP Chemotherapy or Up-Front Surgery in Resectable Locally Advanced Oral Squamous Cell Carcinoma

Next Previous
Trial Profile

A Multi-Center, Randomized Phase III Study of Neoadjuvant Anti-PD-1 Immunotherapy Plus TP Chemotherapy Versus TP Chemotherapy or Up-Front Surgery in Resectable Locally Advanced Oral Squamous Cell Carcinoma

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 04 Apr 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Camrelizumab (Primary) ; Cisplatin; Docetaxel
  • Indications Carcinoma; Mouth neoplasm; Squamous cell cancer
  • Focus Therapeutic Use
  • Acronyms NEOPCOSCC

Most Recent Events

  • 02 Feb 2024 Status changed from not yet recruiting to recruiting.
  • 26 Oct 2023 Planned initiation date changed from 1 Aug 2023 to 20 Nov 2023.
  • 28 Jul 2023 Planned initiation date changed from 1 May 2023 to 1 Aug 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top